Repligen Corporation $RGEN Stock Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC trimmed its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 28.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 700,626 shares of the biotechnology company’s stock after selling 280,357 shares during the period. Repligen comprises 4.1% of Conestoga Capital Advisors LLC’s holdings, making the stock its 3rd largest position. Conestoga Capital Advisors LLC’s holdings in Repligen were worth $134,681,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. United Capital Financial Advisors LLC bought a new position in shares of Repligen in the 2nd quarter valued at about $380,756,000. Maverick Capital Ltd. bought a new stake in Repligen during the first quarter worth about $178,946,000. William Blair Investment Management LLC bought a new stake in Repligen during the second quarter worth about $107,593,000. Bamco Inc. NY bought a new stake in Repligen during the second quarter worth about $102,121,000. Finally, TimesSquare Capital Management LLC acquired a new position in Repligen during the second quarter valued at approximately $60,984,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of a number of analyst reports. Weiss Ratings downgraded Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday. JPMorgan Chase & Co. upped their price objective on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Barclays increased their price objective on Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Canaccord Genuity Group raised their target price on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Finally, Royal Bank Of Canada raised their target price on shares of Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $178.57.

Repligen Stock Down 0.0%

Repligen stock opened at $178.20 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The company’s 50-day moving average is $177.75 and its 200-day moving average is $145.42. The firm has a market capitalization of $11.39 billion, a PE ratio of -848.53, a P/E/G ratio of 3.05 and a beta of 1.11. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The business had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. During the same period last year, the business posted $0.46 EPS. Repligen’s revenue was up 10.9% on a year-over-year basis. Sell-side analysts anticipate that Repligen Corporation will post 2.07 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.